|
Nov 14
|
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
|
|
Nov 12
|
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%
|
|
Oct 10
|
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
|
|
Jun 22
|
Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
|
|
Jun 13
|
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
|
|
May 11
|
Xencor First Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
|
|
May 9
|
Xencor Reports First Quarter 2024 Financial Results
|
|
May 6
|
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
May 3
|
Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares
|
|
May 2
|
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
|
Apr 9
|
Xencor Appoints Bart Cornelissen as Chief Financial Officer
|
|
Mar 8
|
Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR)
|
|
Mar 7
|
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
|
|
Feb 15
|
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
|
|
Jan 3
|
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 3
|
Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
|
|
Dec 30
|
Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares
|
|
Dec 10
|
Xencor (NASDAQ:XNCR) shareholders are up 7.7% this past week, but still in the red over the last three years
|
|
Nov 7
|
Xencor Reports Third Quarter 2023 Financial Results
|